Bio Medica Laboratories Limited (BMLL)
சுருக்கம்
The board meets on 13 Nov 2026 to consider the Q2 FY27 results.
பங்குச் சந்தை செயல்பாடு12 நவ. 2026
- டெலிவரி
- 66.67% எதிர் சராசரி 88.01%
- வால்யூம் அதன் சராசரியுடன் ஒப்பீடு
- 0.2×
- பல்க் & பிளாக் டீல்கள்
- 60 நாட்களில் 5
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 13 நவ. 2026 (Q2 FY27)
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 27 ஜூலை 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 13 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)Bio Medica Laboratories Limited-இன் இயக்குநர் குழுக் கூட்டம் 13 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
BMLL delivery percentage and bulk deals
க்கான NSE EOD தரவு
On Thu, 12 Nov 2026, 66.67% of the BMLL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 88.01%. That is lower than usual for this stock. Turnover was only ₹13 lakh, so a handful of trades can move this figure. Volume was 0.2 times its average, well below normal. 5 bulk or block deals were reported in BMLL in the last 60 days: ₹3 Cr bought and ₹3 Cr sold.
கடந்த 5 அமர்வுகளில் டெலிவரி: 62.5% · 100.0% · 88.5% · 72.9% · 66.7%
| தேதி | பக்கம் | எதிர்தரப்பு | மதிப்பு | விலை | அளவு | வகை |
|---|---|---|---|---|---|---|
| 27 அக். | வாங்கு | Oswal Energies Limited | ₹1.17 கோடி | ₹146.00 | 80,000 | பல்க் |
| 27 அக். | விற்க | Jayant Babulal Bokadia | ₹1.17 கோடி | ₹146.00 | 80,000 | பல்க் |
| 26 அக். | வாங்கு | Oswal Energies Limited | ₹2.10 கோடி | ₹146.00 | 144,000 | பல்க் |
| 26 அக். | விற்க | Dixit Jitendra Bokadia | ₹1.09 கோடி | ₹146.00 | 75,000 | பல்க் |
| 26 அக். | விற்க | Ratan Babulal Bokadia | ₹1.01 கோடி | ₹146.00 | 69,000 | பல்க் |
பங்குச் சந்தை வெளியிட்டவற்றின் விளக்கம், பரிந்துரை அல்ல. "accumulation" அல்லது "லாங் பில்டப்" போன்ற பெயர்கள் எண்களில் உள்ள ஒரு வடிவத்தை குறிக்கின்றன. டெலிவரி எவ்வாறு பகுப்பாய்வு செய்யப்படுகிறது
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Bio Medica Laboratories Limited has announced the voting results of its 11th Annual General Meeting held on September 28, 2026. All four resolutions were passed with 100% of polled votes in favour, representing 83.47% overall voting participation across 10,496,541 polled shares. Notably, shareholders passed a special resolution approving an increase in the investment limit for registered Foreign Portfolio Investors (FPIs) / Foreign Institutional Investors (FIIs) up to 49% of the paid-up equity share capital. Other approved resolutions included the adoption of FY26 financial statements, the reappointment of director Mr. Mukesh Mehta, and the appointment of the secretarial auditor.
- Special resolution passed to increase total FPI/FII shareholding limit up to 49% of paid-up equity capital
- Overall voter turnout stood at 83.4715% with 10,496,541 votes polled out of 12,575,001 total shares
- All resolutions passed unanimously with 100% of votes cast in favour and 0 votes against
- Only 18 shareholders attended the AGM via video conference (2 promoters and 16 public shareholders)
Bio Medica Laboratories Limited has issued the notice convening its 11th Annual General Meeting (AGM) on September 28, 2026, via video conferencing. The company is seeking shareholder approval for routine business, including the adoption of FY26 financial statements and director re-appointment. Notably, a special resolution is proposed to increase the collective investment limit for Foreign Portfolio Investors (FPIs)/FIIs up to 49% of the paid-up equity share capital. Additionally, the appointment of M/s Vishakha Agrawal & Associates as Secretarial Auditor for a 5-year tenure is placed for approval.
- 11th AGM scheduled for September 28, 2026, at 02:00 PM IST via video conferencing
- Special resolution proposed to raise FPI/FII shareholding limit up to 49% of paid-up equity share capital
- Appointment of Secretarial Auditor M/s Vishakha Agrawal & Associates for a term of 5 years (FY26 to FY31)
- Adoption of audited financial statements for the financial year ended March 31, 2026
Bio Medica Laboratories Limited has announced remote e-voting facilities for its 11th Annual General Meeting scheduled for Monday, September 28, 2026. The cut-off date to determine shareholder voting eligibility is Tuesday, September 22, 2026. Remote e-voting opens on Friday, September 25, 2026, and concludes on Sunday, September 27, 2026, at 5:00 PM IST via the NSDL platform. CS Vishakha Agrawal has been appointed as the scrutinizer for the process.
- 11th Annual General Meeting scheduled for Monday, September 28, 2026
- Cut-off date for e-voting eligibility set for Tuesday, September 22, 2026
- Remote e-voting window runs from September 25, 2026, to September 27, 2026 (5:00 PM)
- NSDL to act as the e-voting platform provider with CS Vishakha Agrawal appointed as Scrutinizer
Bio Medica Laboratories Limited has approved the appointment of M/s. Vishakha Agrawal & Associates, Practicing Company Secretaries, as its Secretarial Auditor. The appointment took place at the Board meeting held on September 02, 2026. The tenure covers a period of 5 consecutive years spanning FY 2025-26 to FY 2029-30. The appointment is subject to approval by shareholders at the ensuing Annual General Meeting.
- Board approved appointment on September 02, 2026
- Appointed M/s. Vishakha Agrawal & Associates as Secretarial Auditor
- Tenure spans 5 consecutive years from FY 2025-26 to FY 2029-30
- Appointment remains subject to shareholder approval at the upcoming AGM
Bio Medica Laboratories Limited (BMLL) announced the approval of all four postal ballot resolutions by shareholders with 100% of votes cast in favor. The key approval includes a Special Resolution to sell and disinvest the company's 51% equity shareholding in its subsidiary, Vitamax Private Limited. Additionally, shareholders approved higher thresholds for loans, guarantees, and securities under Sections 185 and 186, as well as material related-party transactions under Section 188. Out of 12,575,001 total outstanding equity shares, 10,336,541 shares (82.20% turnout) participated in the remote e-voting.
- 100% of votes cast (10,336,541 votes) were in favour of selling the 51% stake in subsidiary Vitamax Private Limited
- Overall voting turnout was 82.20% across 18 participating shareholders out of 347 total members
- Promoter group polled 8,512,541 votes (99.9957% of promoter holding), all in favour
- Shareholders also approved enhanced limits for inter-corporate loans, guarantees, and investments under Sections 185 and 186
Bio Medica Laboratories Limited (BMLL) has appointed Ms. Khushi Gupta as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) effective August 14, 2026. This appointment fills a casual vacancy created by the resignation of the previous officer. Ms. Gupta is a qualified Company Secretary and an Associate Member of the Institute of Company Secretaries of India (ICSI). The board approved the appointment following a recommendation from the Nomination & Remuneration Committee.
- Appointment of Ms. Khushi Gupta effective from August 14, 2026
- Ms. Gupta is an Associate Member of ICSI with Membership No. A78179
- The role covers Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) designations
- Appointment fills a casual vacancy arising from the resignation of the previous incumbent
Bio Medica Laboratories Limited has announced the resignation of Ms. Pratiksha Bhandari from the post of Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). Her resignation is effective from the close of business hours on August 13, 2026. The resignation is cited to be purely due to personal reasons and other professional commitments, with no other material reasons reported. The company will be required to appoint a successor to maintain statutory compliance.
- Ms. Pratiksha Bhandari resigned as Company Secretary, Compliance Officer, and KMP.
- Resignation effective from the close of business hours on August 13, 2026.
- Stated reason: Personal reasons and other professional commitments with no other material reasons.
Bio Medica Laboratories Limited (BMLL) has informed the exchange that it is exempt from submitting the Corporate Governance Report for the quarter ended June 30, 2026. This exemption is granted under Regulation 15(2) of SEBI (LODR) Regulations, 2015, which applies to entities listed on the SME Exchange. The regulation specifically exempts companies with a paid-up equity capital not exceeding ₹10 crore and a net worth not exceeding ₹25 crore. As an NSE SME Platform listed entity, BMLL is not required to comply with the governance provisions specified in Regulations 17 to 27.
- Exemption claimed under Regulation 15(2) of SEBI (LODR) Regulations, 2015 for the quarter ended June 30, 2026.
- Exemption applies to SME entities with paid-up capital not exceeding ₹10 crore.
- Exemption applies to SME entities with net worth not exceeding ₹25 crore.
- The company is listed on the NSE SME Platform, qualifying it for reduced reporting requirements.
Bio Medica Laboratories Limited (BMLL) has initiated a postal ballot to seek shareholder approval for the disinvestment of its 51% stake in subsidiary Vitamax Private Limited. The company is also requesting an increase in its investment and loan limits under Section 186 to ₹100 Crores. Furthermore, it seeks approval for Related Party Transactions (RPT) up to ₹50 Crores for the 2026-27 financial year. The e-voting period for these resolutions runs from July 29, 2026, to August 27, 2026.
- Proposal to sell or disinvest 51% equity shareholding in subsidiary Vitamax Private Limited
- Request to increase the threshold for loans, guarantees, and investments to ₹100 Crores
- Proposed limit for Related Party Transactions set at ₹50 Crores for FY 2026-27
- E-voting period scheduled from July 29, 2026, to August 27, 2026
- Cut-off date for eligibility to vote was Friday, July 24, 2026
Bio Medica Laboratories Limited (BMLL) reported a 23.7% year-on-year increase in consolidated Profit Before Tax to ₹16.25 Cr for FY26. Despite the profit growth, the company's cash flow position remains strained, with Net Cash from Operating Activities worsening to a negative ₹6.03 Cr, largely driven by a significant ₹17.90 Cr increase in inventory. The board has also initiated a postal ballot to seek shareholder approval for the disinvestment of a subsidiary and to increase limits for inter-corporate loans, guarantees, and related party transactions.
- Consolidated Profit Before Tax increased to ₹1625.41 Lakhs in FY26 from ₹1314.27 Lakhs in FY25.
- Net Cash Flow from Operating Activities was negative ₹603.46 Lakhs, compared to negative ₹457.42 Lakhs in the previous year.
- Inventory levels saw a massive outflow of ₹1790.42 Lakhs, indicating significant working capital blockage.
- Total borrowings increased by ₹1049.09 Lakhs during the year to fund operations and a ₹281.15 Lakhs capex.
- Board proposed a postal ballot for the sale/disinvestment of a subsidiary company and approval of material related party transactions.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
